Authors:
Mehta, PD
Pirttila, T
Patrick, BA
Barshatzky, M
Mehta, SP
Citation: Pd. Mehta et al., Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease, NEUROSCI L, 304(1-2), 2001, pp. 102-106
Authors:
Schupf, N
Patel, B
Silverman, W
Zigman, WB
Zhong, N
Tycko, B
Mehta, PD
Mayeux, R
Citation: N. Schupf et al., Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome, NEUROSCI L, 301(3), 2001, pp. 199-203
Authors:
Sigurdsson, EM
Scholtzova, H
Mehta, PD
Frangione, B
Wisniewski, T
Citation: Em. Sigurdsson et al., Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice, AM J PATH, 159(2), 2001, pp. 439-447
Authors:
Tsiouris, JA
Mehta, PD
Patti, PJ
Madrid, RE
Raguthu, S
Barshatzky, MR
Cohen, IL
Sersen, E
Citation: Ja. Tsiouris et al., Alpha(2) macroglobulin elevation without an acute phase response in depressed adults with Down's syndrome: implications, J INTEL DIS, 44, 2000, pp. 644-653
Authors:
Tapiola, T
Pirttila, T
Mikkonen, M
Mehta, PD
Alafuzoff, I
Koivisto, K
Soininen, H
Citation: T. Tapiola et al., Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease, NEUROSCI L, 280(2), 2000, pp. 119-122
Authors:
Tapiola, T
Pirttila, T
Mehta, PD
Alafuzoff, I
Lehtovirta, M
Soininen, H
Citation: T. Tapiola et al., Relationship between apoE genotype and CSF beta-amyloid (1-42) and tan in patients with probable and definite Alzheimer's disease, NEUROBIOL A, 21(5), 2000, pp. 735-740
Authors:
Mehta, PD
Pirttila, T
Mehta, SP
Sersen, EA
Aisen, PS
Wisniewski, HM
Citation: Pd. Mehta et al., Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, ARCH NEUROL, 57(1), 2000, pp. 100-105
Authors:
Pirttila, T
Haanpaa, M
Mehta, PD
Lehtimaki, T
Citation: T. Pirttila et al., Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster, ACT NEUR SC, 102(2), 2000, pp. 94-98
Authors:
Hulstaert, F
Blennow, K
Ivanoiu, A
Schoonderwaldt, HC
Riemenschneider, M
De Deyn, PP
Bancher, C
Cras, P
Wiltfang, J
Mehta, PD
Iqbal, K
Pottel, H
Vanmechelen, E
Vanderstichele, H
Citation: F. Hulstaert et al., Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF, NEUROLOGY, 52(8), 1999, pp. 1555-1562